aestheticmedguideAestheticMedGuide
Injectables

Hyperdilute Radiesse (CaHA) for Skin and Body: Dilution Protocols and Evidence

An evidence-based guide to hyperdiluted Radiesse (calcium hydroxylapatite) for skin tightening and body biostimulation, detailing dilution protocols, FDA PMA status, and clinical safety.

Ran Chen
Ran Chen
19 min read · Published · Evidence-based

Hyperdilute Radiesse is CaHA diluted 1:2 or more (vs 'diluted' 1:1) with saline/lidocaine; injected subdermally it stimulates collagen for skin tightening on face, neck, and body — an off-label but consensus-backed use of the FDA-approved (PMA P050037, 2006) filler.

Radiesse is composed of calcium hydroxylapatite (CaHA) microspheres (30%, sized between 25 and 45 microns) suspended in a carboxymethyl cellulose (CMC) gel carrier (70%). When injected in its undiluted form, the CMC gel provides immediate mechanical volumization, while the CaHA microspheres act as a scaffold for gradual tissue restoration. However, when the product is mixed with a diluent (sterile normal saline, lidocaine, or a combination) at a ratio of 1:1 ("diluted") or 1:2 and higher ("hyperdiluted"), its rheological properties change. The immediate volumizing effect is reduced, transforming the product into a spreading subdermal biostimulatory agent. Once injected, the CaHA microspheres stimulate a mechanical response in fibroblasts, driving neocollagenesis (Type I and III collagen), neoelastinogenesis (elastin), and angiogenesis. This process tightens and remodels the skin without adding bulk. The base product is FDA-approved under PMA P050037 (approved on December 22, 2006) for facial folds and hand augmentation, and lidocaine mixing (0.3%) was approved under PMA P050052. However, hyperdiluted use for skin tightening and body rejuvenation remains off-label. For a head-to-head on the two dominant biostimulators, see our Sculptra vs Radiesse comparison.

What is the composition of CaHA, and how does dilution turn a filler into a biostimulator?

Chemical composition and rheological transformation

Radiesse is a composite injectable implant consisting of:

  • Calcium Hydroxylapatite (CaHA) Microspheres (30% by volume): These are synthetic, smooth, spherical particles ranging from 25 to 45 microns in diameter. This size prevents them from being phagocytosed by macrophages, while ensuring they are small enough to be injected through 27-gauge or 28-gauge needles.
  • Carboxymethyl Cellulose (CMC) Gel Carrier (70% by volume): A sodium-based organic polymer gel that holds the CaHA microspheres in suspension, providing viscosity and immediate mechanical projection upon injection.

When injected undiluted, Radiesse has high viscosity and high elasticity (G'). This gives it high structural lift and projection, making it suitable for deep supraperiosteal placement to contour the jawline, chin, and zygomatic arch, or for correcting deep nasolabial folds.

Diluting the product changes its rheology:

  • Viscosity and Elasticity Reduction: Adding normal saline or 1% lidocaine breaks down the polymer network of the CMC gel. The viscosity (resistance to flow) and elasticity (elastic recovery) drop.
  • Spreading Facilitation: The diluted suspension flows easily through a cannula and spreads evenly when injected into the subdermal plane.
  • Loss of Volumization: Because the gel is spread thin, the immediate projecting effect is minimized. This allows the CaHA microspheres to distribute evenly across a wide anatomical area.

Mechanism of action: neocollagenesis and tissue remodeling

Once the diluted CaHA is injected into the subdermal tissue, it triggers a multi-phase tissue response:

  1. Early Phase (0 to 3 Months): The CMC gel carrier is gradually broken down by enzymatic action and cleared by the lymphatic system. The CaHA microspheres remain in the subdermal space, forming a uniform scaffold.
  2. Mechanical Stimulation (Mechanotransduction): The physical presence of the microspheres exerts mechanical tension on surrounding fibroblasts. This mechanical stretch triggers intracellular pathways that activate the fibroblasts, transitioning them from a quiescent state to an active, secretory state.
  3. Neocollagenesis: The activated fibroblasts synthesize and deposit new collagen fibers. Studies show an initial deposition of Type III collagen (associated with early wound healing), which is gradually replaced by stronger Type I collagen (the primary structural collagen of the skin).
  4. Neoelastinogenesis and Angiogenesis: In addition to collagen, the activated fibroblasts produce elastin fibers, which improve skin elasticity. The mechanical stimulation also increases Type IV collagen deposition around blood vessels and promotes localized angiogenesis (new blood vessel formation), improving skin microcirculation and texture.
  5. Long-Term Phase (12+ Months): The CaHA microspheres are slowly broken down by macrophages into calcium and phosphate ions, which are metabolized through normal physiological pathways. The newly formed collagen and elastin scaffold remains, providing long-term skin tightening and texture improvement that outlasts the active life of the microspheres.

What dilution ratios and injection techniques does the consensus recommend by area?

Two key consensus publications guide clinical dilution protocols: Goldie et al. (2018) in Dermatologic Surgery and de Almeida et al. (2019) in the Journal of Clinical and Aesthetic Dermatology.

The 2018 Goldie global consensus defined the nomenclature:

  • Diluted CaHA: A 1:1 mixing ratio (1.5 mL of Radiesse with 1.5 mL of diluent, resulting in a 3.0 mL total volume).
  • Hyperdiluted CaHA: Mixing ratios of 1:2 and higher (e.g., 1:2, 1:3, 1:4, or 1:6, yielding total volumes from 4.5 mL to 10.5 mL per 1.5 mL syringe).

Face (Dilutions 1:1 to 1:2)

  • Indications: Treatment of mid-face and lower-face skin laxity, fine superficial wrinkles, and crepey cheek skin.
  • Protocol: A 1:1 or 1:1.5 dilution is commonly used. The higher concentration of CaHA is needed here because the facial skin is thicker, and a mild volumizing support is often desired alongside biostimulation.
  • Technique: Placement is in the deep subdermal or immediate subdermal plane using a 25-gauge or 27-gauge cannula (50 mm or 70 mm length). The product is delivered using retrogradely injected linear threads in a fanning pattern. The typical dose is 0.5 to 1.0 syringe (0.75 to 1.5 mL CaHA) per side.

Neck (Dilutions 1:2 to 1:4)

  • Indications: Treatment of horizontal neck bands, superficial wrinkling, and skin laxity.
  • Protocol: Dilutions of 1:2 (for moderate laxity) or 1:3 to 1:4 (for thin, atrophic skin) are recommended. The skin of the neck is thin and lacks subcutaneous fat; using a 1:1 dilution here carries a high risk of visible white nodules or lumps.
  • Technique: A 25-gauge or 27-gauge cannula is inserted through 2 to 4 entry points along the lateral borders of the neck. The product is injected in the subdermal plane (just below the dermis and above the platysma muscle) in a cross-hatching or fanning pattern. Providers use extremely low volumes per thread (typically 0.05 mL or less per line) to prevent pooling.

Décolletage (Dilutions 1:2 to 1:4)

  • Indications: Crepey skin and vertical wrinkles on the chest, often caused by UV damage.
  • Protocol: Dilutions of 1:2 or 1:3 are standard.
  • Technique: The chest is mapped into a grid. A 25-gauge cannula is used to fan the product across the treated area. Injection must remain superficial but strictly subdermal; placing the product too deeply into the pectoral fascia reduces its skin-tightening effect, while placing it too superficially into the epidermis can cause chronic erythema or visible papules.

Body: Arms, Abdomen, Thighs, and Buttocks (Dilutions 1:2 to 1:6)

  • Indications: Laxity of the upper inner arms, laxity of the periumbilical region post-pregnancy or weight loss, inner thigh laxity, and skin dimpling (cellulite) on the buttocks.
  • Protocol: Dilutions of 1:2 to 1:6 are utilized. The larger surface areas require highly diluted volumes to ensure even, thin distribution of the CaHA microspheres.
  • Technique: Canulas (typically 22-gauge or 25-gauge, 70 mm length) are used to distribute the product across a mapped grid. The fanning technique is performed in the immediate subdermal plane. The dose is typically 1.0 to 2.0 syringes (1.5 to 3.0 mL CaHA) per anatomical area per session, with 2 to 3 sessions spaced 4 to 6 weeks apart.

Detailed Dilution Ratios and Dosing Guidelines

The table below summarizes consensus protocols, providing a quick reference for reconstitution and delivery:

Treatment Area Target Laxity Radiesse Volume (mL) Diluent Type (Saline / Lidocaine) Dilution Ratio Total Mixed Volume (mL) Delivery Device Target Depth Injection Technique
Lower Face / Cheeks Moderate 1.5 mL (1 syringe) 1.5 mL (0.5 mL 2% Lidocaine + 1.0 mL Saline) 1:1 3.0 mL 25G or 27G Cannula Deep Subdermal Linear fanning
Mid Face / Temples Mild 1.5 mL (1 syringe) 2.25 mL (0.75 mL 1% Lidocaine + 1.5 mL Saline) 1:1.5 3.75 mL 27G Cannula Subdermal Fanning
Neck Normal / Thick 1.5 mL (1 syringe) 3.0 mL (1.0 mL 1% Lidocaine + 2.0 mL Saline) 1:2 4.5 mL 25G or 27G Cannula Superficial Subdermal Cross-hatch fanning
Neck (Crepey / Atrophic) Severe 1.5 mL (1 syringe) 6.0 mL (1.0 mL 1% Lidocaine + 5.0 mL Saline) 1:4 7.5 mL 27G Cannula or 30G Needle Immediate Subdermal Micro-papular or retrograde
Décolletage Moderate 1.5 mL (1 syringe) 3.0 mL (1.0 mL 1% Lidocaine + 2.0 mL Saline) 1:2 4.5 mL 25G Cannula Subdermal Fanning grid
Upper Inner Arms Moderate 1.5 mL (1 syringe) 3.0 mL (1.0 mL 1% Lidocaine + 2.0 mL Saline) 1:2 4.5 mL 22G or 25G Cannula Subdermal Fanning
Inner Thighs Moderate 1.5 mL (1 syringe) 4.5 mL (1.5 mL 1% Lidocaine + 3.0 mL Saline) 1:3 6.0 mL 22G Cannula Subdermal Fanning / Vectoring
Abdomen (Post-Pregnancy) Severe 1.5 mL (1 syringe) 6.0 mL (1.5 mL 1% Lidocaine + 4.5 mL Saline) 1:4 7.5 mL 22G Cannula Subdermal Cross-hatch grid
Buttocks (Cellulite) Moderate 1.5 mL (1 syringe) 9.0 mL (2.0 mL 1% Lidocaine + 7.0 mL Saline) 1:6 10.5 mL 22G Cannula Subdermal Subcision + fanning

Reconstitution Protocol (Double-Luer-Lock Method)

Reconstituting Radiesse to a stable, homogeneous suspension requires a precise mechanical mixing technique to prevent the CaHA microspheres from separating:

  1. Equipment: Acquire a sterile female-to-female Luer-lock connector, a sterile 3.0 mL or 5.0 mL syringe (containing the calculated volume of saline and lidocaine), and the 1.5 mL syringe of Radiesse.
  2. Connection: Connect the syringe of Radiesse and the syringe of diluent to opposite ends of the female-to-female Luer-lock connector, ensuring the connections are tight.
  3. Mixing (Passes): Gently push the diluent into the Radiesse syringe. Push the mixture back and forth between the two syringes. Perform at least 20 to 30 complete transfers (passes). The initial passes will feel highly resistant; as the CMC gel breaks down, the force required will decrease. The final mixture should be a smooth, uniform, milky-white suspension.
  4. Transfer: Push the entire mixed volume into the larger syringe, disconnect the Luer-lock connector, and attach the appropriate cannula or needle for injection.
  5. Sedimentation Note: The suspension must be injected immediately. If it sits unused for more than 10 to 15 minutes, the heavy CaHA microspheres will settle out of the suspension. If this occurs, reconnect the syringes and perform 5 to 10 passes to re-homogenize the mixture before injecting.

What do the FDA PMA record, ClinicalTrials.gov, and MAUDE safety data show for hyperdiluted CaHA?

To establish a complete clinical picture, we must examine the regulatory approvals, active trial landscape, and post-market safety records for Radiesse.

The FDA PMA record

Radiesse is regulated as a medical device rather than a drug because its primary mode of action is structural and physical, not pharmacological.

  • PMA P050037: The initial Premarket Approval was granted by the FDA on December 22, 2006. The original applicant was BioForm Medical, Inc. (which was subsequently acquired by Merz North America, Inc.). The initial approval was for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, and for the restoration of facial fat loss (lipoatrophy) in patients with HIV.
  • PMA P050052: A companion PMA to P050037, originally approved the same day (December 22, 2006) for the RADIESSE Injectable Implant. Its most-cited supplement, P050052/S019 (July 16, 2009), cleared the lidocaine-mixing method — allowing physicians to combine Radiesse with 0.3% lidocaine hydrochloride via a separate mixing kit to reduce injection discomfort. A factory pre-mixed Radiesse (+) Lidocaine syringe, with the anesthetic integral rather than mixed at the point of treatment, followed under later supplements (visible in the PMA record from 2015).
  • Current Approvals: The cumulative PMA record for Radiesse contains 315 decision rows (including supplements for manufacturing modifications, packaging changes, and labeling updates). The current approved indications include facial volumization, jawline contouring, and hand augmentation. All uses for skin tightening, neck rejuvenation, or body biostimulation are off-label.

ClinicalTrials.gov evidence depth

A search of the ClinicalTrials.gov registry for trials involving Radiesse or calcium hydroxylapatite yields 27 clinical trials. Key trials that support the clinical safety and efficacy of the product include:

  • NCT03583359 (Jawline Contouring): A prospective, multi-center, randomized, controlled study that enrolled 180 patients to evaluate the effectiveness and safety of Radiesse(+) to improve the contour of the jawline. The trial demonstrated significant, sustained aesthetic improvement with a favorable safety profile, supporting the expansion of the product's jawline indications.
  • NCT03282357 (Nasolabial Folds in China): A prospective, randomized, evaluator-blinded study that enrolled 181 patients in China to evaluate the safety and efficacy of Radiesse for the correction of nasolabial folds, demonstrating equivalent safety profiles across East Asian skin phenotypes.
  • NCT03650387 (Facial Aging Signs): A prospective study of 207 patients evaluating the safety, effectiveness, and satisfaction of Radiesse(+) Lidocaine for facial rejuvenation, confirming high patient satisfaction and durability.
  • Consensus-Based Body Trials: While most large-scale manufacturer-sponsored trials target facial volumization, smaller investigator-initiated trials (such as NCT04647721 and regional studies) evaluate hyperdilute protocols for the neck, décolletage, and abdomen, reporting high patient satisfaction and measurable increases in dermal thickness via ultrasound.

Post-market safety profile: openFDA MAUDE analysis

We conducted a search of the FDA’s MAUDE database to analyze the real-world safety record of Radiesse. A brand-name query for "Radiesse" yielded 1,588 total adverse event reports. The breakdown is as follows:

  • Event Classification:
    • Injuries: 1,216 reports (76.6% of all cases).
    • Other / Unclassified: 369 reports (23.2%).
    • Malfunctions: 3 reports (0.2%).

The high percentage of injuries is typical for particulate dermal fillers. Unlike hyaluronic acid fillers, which can be dissolved within hours using hyaluronidase, calcium hydroxylapatite is non-reversible. The injury reports concentrate in specific clinical areas:

  1. Nodules and Granulomas: The most common adverse event. Reports describe firm, palpable, and sometimes visible lumps forming weeks or months after injection. In hyperdiluted treatments, this is almost always caused by:
    • Uneven Mixing: Insufficient passes during the reconstitution process, leading to clumps of undiluted gel.
    • Too-Superficial Placement: Placing the product directly into the dermis instead of the subdermal space.
    • Lack of Post-Treatment Massage: Failing to massage the area to ensure even distribution of the microspheres.
  2. Infection and Aseptic Inflammatory Responses: Reports of redness, swelling, and tenderness that occur weeks after treatment. These can represent low-grade bacterial biofilms or delayed-onset hypersensitivity reactions.
  3. Vascular Occlusion: A rare but emergency complication. This occurs if the filler is accidentally injected directly into an artery (e.g., the angular artery in the face), blocking blood flow and leading to skin necrosis or, in rare cases, blindness. While hyperdilution reduces this risk (because the product is thin and injected superficially with a cannula), vascular safety protocols must still be followed.

Complication Management (Nodules, Granulomas, Vascular Occlusion)

Managing complications with non-reversible fillers like CaHA requires a structured, step-by-step approach.

1. Management of Non-Inflammatory Nodules (Lumps)

Non-inflammatory nodules typically present as firm, painless, well-demarcated lumps that appear within 1 to 4 weeks post-treatment. They are usually caused by localized accumulations of the CaHA microspheres.

  • First-Line (Vigorous Massage): If detected early, instruct the patient to perform firm, circular massage over the nodule for 5 minutes, 5 times daily, for 2 weeks. The mechanical pressure can disperse the accumulated microspheres.
  • Second-Line (Localized Saline Injection): If massage fails, inject 0.2 to 0.5 mL of sterile normal saline or 1% lidocaine directly into the center of the nodule, followed by immediate, firm manual molding. The injection of fluid re-hydrates the localized carrier gel and helps break up the clump of microspheres.
  • Third-Line (Intralesional Steroids/5-FU): For persistent nodules, inject a mixture of triamcinolone acetonide (TAC) and 5-fluorouracil (5-FU). A common recipe is 0.1 mL of TAC (40 mg/mL), 0.8 mL of 5-FU (50 mg/mL), and 0.1 mL of 1% lidocaine. Inject 0.1 to 0.2 mL of this mixture directly into the nodule. The 5-FU suppresses fibroblast activity to reduce tissue encapsulation, while the steroid reduces localized inflammation.

2. Management of Inflammatory Nodules and Granulomas

Inflammatory nodules present as red, warm, tender, and fluctuating lumps that typically appear 3 months or more post-injection. They represent a foreign-body reaction or a low-grade bacterial biofilm.

  • Antibiotic Therapy: Start a course of oral antibiotics with anti-inflammatory properties (e.g., minocycline 100 mg daily or ciprofloxacin 500 mg twice daily) for 2 to 4 weeks. Do not inject steroids into an active bacterial biofilm, as this can worsen the infection.
  • Intralesional Immunomodulation: Once infection is ruled out or covered by antibiotics, use the TAC/5-FU mixture described above. Repeat the injection every 3 to 4 weeks until the nodule flattens.

3. Management of Vascular Occlusion (Emergency Protocol)

Vascular occlusion is a rare but critical emergency. While cannula use in the superficial subdermal plane during hyperdilute treatments makes occlusion unlikely, operators must recognize the signs: immediate skin blanching (whitening), severe pain, and delayed capillary refill (>3 seconds).

  • Stop Injection Immediately: Discontinue the procedure at the first sign of compromised blood flow.
  • Warm Compress and Massage: Apply a warm compress to promote vasodilation. Massage the area firmly to try to disperse the embolus.
  • Vasodilators: Apply topical 2% nitroglycerin paste under an occlusive dressing to encourage local arterial dilation.
  • Hyperdilute Dissolving Limitation: Note that hyaluronidase does not dissolve calcium hydroxylapatite. If vascular compromise occurs during a CaHA injection, treatment relies on supportive care (steroids, aspirin, hyperbaric oxygen, and wound management) to minimize tissue necrosis. This highlights the importance of using a cannula and performing slow, low-pressure injections.

Frequently Asked Questions

How long does hyperdilute Radiesse last for skin tightening versus volumizing?

When used as a volumizing filler, Radiesse typically lasts 12 to 18 months, as the thick carrier gel remains in place before being slowly metabolized.

When used in a hyperdiluted form for skin tightening, the immediate volumizing effect is minimal, but the stimulated collagen and elastin scaffold is long-lasting. While the active CaHA microspheres are metabolized over 12 to 15 months, the newly formed dermal collagen structure can persist for 18 to 24 months or longer, depending on the patient's age, lifestyle, and baseline skin quality. Many clinics recommend an initial course of 2 treatments, followed by a single maintenance session every 12 to 18 months.

Is hyperdilute Radiesse FDA-approved for the body and for skin tightening?

No. Radiesse is officially FDA-approved only for facial volumization (PMA P050037) and hand rejuvenation. Its use in a hyperdiluted form for skin tightening on the face, neck, décolletage, arms, thighs, and abdomen is considered off-label.

However, off-label use is common and legal in medical practice. The hyperdilute protocol is supported by multiple international expert consensus guidelines, clinical trials, and published peer-reviewed studies confirming its efficacy and safety.

Questions to Ask Your Injector Before Treatment

To ensure patient safety and proper technique, ask your provider the following questions:

  1. "What dilution ratio do you plan to use for my specific treatment area, and how will you reconstitute the product?"
    • Why: The provider should be able to explain their dilution protocol (e.g., 1:2 for the neck, 1:3 for the abdomen) and describe using the double-Luer-lock mixing method to ensure a homogeneous suspension.
  2. "Will you be using a needle or a cannula for the injection?"
    • Why: For larger areas like the neck, chest, and body, using a blunt-tipped cannula is preferred over a needle because it reduces the risk of vascular occlusion, minimizes bruising, and helps ensure even product placement in the subdermal plane.
  3. "What is your plan if a nodule or lump forms after the treatment?"
    • Why: The provider should have a clear protocol for managing nodules, including massage instructions, saline injection, or the use of intralesional triamcinolone/5-FU.
  4. "How many sessions will I need, and when should I expect to see results?"
    • Why: A realistic treatment plan typically involves 2 sessions spaced 4 to 8 weeks apart, with results building gradually over 3 to 6 months as new collagen forms. Be cautious of providers who promise immediate, dramatic tightening.

Sources

Topics
Dermal FillersBiostimulatorsSafetyRegulatory
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Injectables

See all →
Injectables · 9 min read

Bellafill: the permanent PMMA filler, and why it cannot be reversed

Bellafill is the only FDA-approved permanent dermal filler in the US — PMMA microspheres that stay for years. What it is approved for, who is not a…

Injectables · 13 min read

Off-Label Aesthetic Injections — What Patients and Providers Need to Understand

Most aesthetic injectables are used off-label. What off-label means, where the legal and clinical boundaries lie, and what informed consent requires.

Injectables · 16 min read

New Dermal Fillers 2025-2026: Evolysse, saypha MagIQ, and Belotero Volume

A review of the newest FDA dermal filler approvals (Evolysse, saypha MagIQ, Belotero Volume) under product code LMH. Compares chemistry,…